Alle afleveringen
282 afleveringen, van nieuw naar oud
-
Episode 156 - Rafiq Hasan - CEO of Complement Therapeutics
21 april 2026 · 21 min
We sit down with Rafiq Hasan, co-founder & CEO of Complement Therapeutics, at their London offices to unpack a milestone-loaded past 6 months. Lees meer
Rafiq shares the company's thesis, based on research from Manchester university, and how in practice they are targeting the complement system.
We also dig into a landmark moment for the company - the recent dosing of patients in OPTI-GAIN, their Phase 1/2 clinical trial targeting Geographic Atrophy, a leading cause of irreversible vision loss.
Another topic of discussion centers around what it's took to build a biotech from the ground up over the past few challenging years.
Definitely worth a listen for anyone building in ophthalmology, gene therapy, or across UK biotech.
-
Episode 155 - Lu Han - CEO & Co-Founder
20 april 2026 · 27 min
In this episode of The BioHub Podcast, Max sits down with Lu Han, CEO of Imviva Biotech. Lees meer
Lu’s journey spans science, venture investing, and now company building, bringing a unique perspective to one of the most competitive areas in biotech.
Imviva is focused on developing off-the-shelf CAR-T therapies, aiming to make cell therapies more scalable and accessible for patients across oncology and autoimmune diseases.
In this conversation, we talk about Lu’s path from scientist to CEO, the global dynamics shaping biotech, and how the next wave of cell therapy is evolving.
-
Episode 154 - Dee Dragon - SVP People Strategy, Admin Operations of Senti Bio
20 april 2026 · 40 min
Today's guest is Dee Dragon, she sits at the interface of People Strategy at Senti Bio. She has entered the industry in the last 6+ years and has really made a difference in the culture at Senti. Not only that, she has co-founded the Biotech CHRO Sisterhood, a movement that is taking the biotech industry by storm. Lees meer
In this episode we explore Dee's journey and how she entered the biotech space, and why her passion in what she does has had a ripple effect through the industry.
-
Episode 153 - Lan Huang - CEO of SEED Therapeutics
17 april 2026 · 36 min
Today’s guest sits at the intersection of cutting-edge science and bold entrepreneurship. Dr. Lan Huang is the Co-Founder, CEO, and Chairman of SEED Therapeutics, where she’s leading the charge in developing next-generation medicines through targeted protein degradation—an approach that’s redefining what’s possible in drug discovery. Lees meer
But she didn’t stop at the lab bench. Lan is also a seasoned biotech entrepreneur, having founded multiple companies across the U.S. and China, including BeyondSpring, which she led to a successful public listing. Across more than 15 years in the industry, she’s built a reputation for translating complex science into real-world treatments.
In this episode, we explore her journey from researcher to CEO, the promise of molecular glue therapies, and what it takes to build a biotech company at the frontier of innovation.
-
Episode 152 - Nazli Azimi - Co-Founder & CEO - Therna Bio
16 april 2026 · 39 min
In this episode of The BioHub Podcast, Amber sits down with Nazli Azimi, Co-founder and CEO of Therna Biosciences. Lees meer
Nazli has previously founded and scaled two biotech companies through to acquisition, and is now focused on building AI-driven platforms to design programmable RNA medicines.
In this conversation, we explore why many first-generation AI drug discovery companies struggled, and why grounding models in real biological questions and high-quality data is critical.
We also discuss what it means to “program” RNA medicines, from designing molecules with specific properties to controlling gene expression at the transcript level.
Nazli shares a real-world example of designing an RNA molecule for a pulmonary fibrosis patient in a matter of days, and what this could mean for the future of personalised therapies.
Where AI in drug discovery starts to move beyond hype and into reality.
-
Episode 151 - Sam Possemiers - CEO, MRM Health
16 april 2026 · 29 min
On this episode we meet Sam Possemiers, CEO at MRM Health, the leading developers of microbiome-based therapeutics within IBD. Lees meer
We discuss the origins of their CORAL platform, which was brought to life in the basement of Ghent University by Willy Verstraete. The concept of "Microbial Resource Management" and how Sam used the profits from his successful CRO, ProDigest, to self-fund the seed and go all-in on MRM.
Sam & the team's latest milestones include ph2b STARFISH-UC trial initiation, & an upcoming study in Pouchitis.
We also close on what it took to raise their €55million Series B, which Sam closed whilst literally halfway up an Alp, and the learnings Sam has taken from that process.
-
Episode 150 - Dr Atta Behfar - Founder of Rion
16 april 2026 · 30 min
In this episode of The BioHub Podcast, Max sits down with Dr. Atta Behfar, Co-Founder of Rion and Professor of Regenerative Medicine at Mayo Clinic. Lees meer
Atta’s work at Mayo led to a key discovery that became the foundation for Rion, a clinical-stage company developing exosome-based therapeutics through its Purified Exosome Product (PEP) platform.
In this conversation, Atta shares the story behind that discovery, how it translated into a company, and the potential of cell-free regenerative medicine to make advanced biologics more accessible to patients.
We also discuss Rion’s progress in wound healing, how the team has been built, and what’s next for their pipeline.
A fascinating look at how breakthrough science becomes real therapies.
-
Episode 149 - Srinivas Rao - CEO & Co-Founder
15 april 2026 · 26 min
In this episode of The BioHub Podcast, Max sits down with Srinivas Rao, CEO of atai Beckley. Lees meer
Srini has been there from the very beginning, helping build atai into one of the leading companies in the mental health and psychedelics space, and now leading the next chapter following the merger with Beckley.
In this conversation, we talk about how atai was founded, the evolution of the psychedelics space, and what it takes to build in one of the most challenging and closely watched areas in biotech.
We also discuss Srini’s transition into the CEO role, the strategy behind the merger, and what’s coming next for the company.
-
Episode 148 - Daniel Fero - Managing Director at OMX Ventures
15 april 2026 · 27 min
We were delighted to welcome Daniel Fero, Managing Director of OMX Ventures, onto the Biohub. He's working at the intersection of science, startups, and investment — where breakthrough research meets real-world impact. Lees meer
Daniel Fero is a venture investor focused on biotech and life sciences, with experience spanning early-stage company building and healthcare innovation. Based in the Greater Boston area — one of the world’s leading hubs for biomedical research — Daniel works closely with scientists and founders to help translate cutting-edge discoveries into companies that can reshape how we understand and treat disease.
He’s particularly engaged in the world of biotech venture capital, where deep scientific insight meets high-stakes decision-making about which ideas are worth backing, scaling, and bringing to market. His work touches everything from university spinouts to emerging therapeutics, reflecting a broader mission: accelerating the path from lab bench to patient impact.
In this conversation, we’ll explore Daniel’s journey into venture investing, what he looks for in early-stage biotech companies, and how innovation is evolving at the frontier of healthcare and life sciences.
-
Episode 147 - Dan Gil - Pelage Pharma
15 april 2026 · 22 min
In todays episode we talk about Dan's career and the work Pelage are doing, leading innovation in the hair loss space.
-
Episode 146 - Jeremy Skillington - CEO of Poolbeg Pharma
14 april 2026 · 33 min
In this episode of The BioHub Podcast, Max sits down in person in London with Jeremy Skillington, CEO of Poolbeg Pharma. Lees meer
Jeremy’s career spans roles at Genentech, Opsona, and Inflazome, which was acquired by Roche before stepping into the CEO role at Poolbeg, a public biotech taking a different approach to drug development.
In this conversation, we talk about how Poolbeg is building a more capital-efficient, data-driven model, the realities of today’s biotech market, and how companies can position themselves to succeed in a tougher funding environment.
It’s a great in-person discussion on what it really takes to build differently in biotech today.
-
Episode 145 - Ashley Zehnder - CEO Fauna Bio
10 april 2026 · 23 min
Today’s guest is Ashley Zehnder, the co-founder and CEO of Fauna Bio—a pioneering biotech company unlocking insights from the natural world to transform human health. Lees meer
With a background in genomics and a passion for translating cutting-edge science into real-world therapies, Ashley is leading a new frontier in drug discovery—one that looks to nature’s own evolutionary experiments to uncover novel treatments for disease.
Under her leadership, Fauna Bio is redefining how we approach medicine by combining comparative biology, machine learning, and massive genomic datasets to identify breakthroughs that traditional methods might miss.
In this episode, we’ll explore Ashley’s journey from scientist to CEO, the bold vision behind Fauna Bio, and how studying the biology of extraordinary animals could reshape the future of healthcare.
-
Episode 144 - Robert Jacks - CEO Sparrow Pharmaceuticals
10 april 2026 · 26 min
In this episode of The BioHub Podcast, Max sits down with Robert Jacks, President and CEO of Sparrow Pharmaceuticals. Lees meer
Robert brings more than 25 years of experience in biotech, having founded or co-founded multiple companies and raised over $300 million across his career. From roles in corporate development at Pfizer to leading companies through development, approval, and exit, he’s seen the industry from every angle.
In this conversation, Robert shares his journey into biotech leadership, the story behind Sparrow, and what it takes to build and scale companies while staying lean and focused.
They also discuss raising capital in today’s market, navigating the challenges of biotech, and where the industry is heading next.
-
Episode 143 - Jenny Yang - CEO & Co-Founder at Outpost Bio
9 april 2026 · 14 min
In this episode, we’re joined by Jenny Yang, Founder and CEO of Outpost Bio, a company building an AI-driven platform to understand how the human microbiome interacts with drugs, food, and other interventions. Lees meer
Jenny shares her journey from machine learning and genomics research through to her PhD at the University of Oxford and experience at Exscientia, before founding Outpost Bio.
We discuss why the microbiome remains an underexplored layer in drug discovery, how advances in AI are enabling more complex biological modelling, and the role of high-quality data in building systems that can translate into real-world impact.
-
Episode 142 - Cary Claiborne - CEO of Adial Pharma
2 april 2026 · 30 min
In this episode of The BioHub Podcast, Max sits down with Cary Claiborne, CEO of Adial Pharmaceuticals. Lees meer
Cary’s career spans finance, M&A, and leadership across multiple public biotech companies before stepping into the CEO role at Adial. The company is focused on developing genetically targeted therapies for addiction, starting with alcohol use disorder.
In this conversation, Cary shares his transition into biotech leadership, what it’s like running a micro-cap clinical-stage company, and how Adial is approaching one of the most complex and underserved areas in medicine.
They also discuss leadership, resilience, and the realities of building and financing biotech companies in today’s market.
-
Episode 141 - Spyros Papapetropoulos - CEO Phragma Therapeutics
1 april 2026 · 47 min
Today’s guest brings one of the broadest and most thoughtful perspectives in neuroscience, spanning clinical practice, drug development, investing, and company building. Lees meer
Dr. Spyros Papapetropoulos is a neurologist, neuroscientist, and biotech leader who has spent his career at the intersection of science, medicine, and innovation. With deep experience across both large pharma and emerging biotech, he has built a reputation for translating complex neuroscience into clear strategic direction - helping shape how new therapies move from idea to impact.
Over the years, Spyros has worked across multiple dimensions of the CNS ecosystem, from research and development through to leadership, investing, and advising. His work has given him a unique vantage point on what it really takes to build successful neuroscience companies, where the field is heading, and why progress in CNS demands a different kind of thinking.
He is also the author of Mind Odyssey, a book that reflects on neuroscience, innovation, and the future of brain health - themes that closely mirror the work he continues to do across the biotech landscape today.
In this conversation, we explore Spyros’ journey through neuroscience, his view on the current state of the CNS biotech ecosystem, where drug development is heading next, and what it takes to build companies, teams, and ideas that can genuinely move the field forward.
-
Episode 140 - Megan McGill - CEO Brenig Therapeutics
1 april 2026 · 33 min
Today’s guest brings a rare blend of medicine, science, and strategy to the frontlines of biotech innovation. Lees meer
Dr. Megan McGill is a physician-scientist and biotech leader with over two decades of experience spanning clinical medicine, neuroscience research, and drug development. Trained as both an MD and PhD, her work has focused deeply on understanding the brain—particularly the mechanisms behind neurodegenerative diseases like Parkinson’s.
But Megan didn’t stop at the lab or the clinic. She’s also worked at the highest levels of strategy consulting with McKinsey & Company, and held leadership roles at cutting-edge biotech firms like Regenxbio and BridgeBio, helping translate scientific breakthroughs into real therapies for patients.
Today, she serves as CEO of Brenig Therapeutics, where she’s leading efforts to develop next-generation, AI-enabled treatments targeting the underlying biology of neurological disease.
In this conversation, we’ll explore her journey from medicine to biotech leadership, the future of drug development, women in leadership positions and what it takes to turn scientific insight into life-changing innovation.
-
Episode 139 - Tess Bevers - CEO & Founder - Novogaia
31 maart 2026 · 10 min
In this episode of The Biohub Podcast, Amber sits down with Tess Bevers CEO and Founder of Novogaia, a company combining AI and mass spectrometry to discover new drug molecules from fungi. Lees meer
We explore why fungi remain one of the most underexplored sources of chemistry in nature, the historical bottlenecks in natural product drug discovery, and how new advances in AI are helping researchers prioritise which molecules could actually become viable drugs.Tess also shares how Novogaia is building its discovery platform, why focus matters in biotech, and what’s driving the company’s move from London to San Francisco.
-
Episode 138- Jason Tardio - COO - Immunic Therapeutics
31 maart 2026 · 29 min
Welcome to another episode of The BioHub. Lees meer
Today I’m joined by Jason Tardio —COO of Immunic Therapeutics, a clinical stage biotech for oral small molecule therapies for chronic inflammatory and autoimmune diseases.
In this episode we explore Jason's awesome background, from starting as a sales rep and climbing the ladder into his position today, as COO.
-
Episode 137 - Steffen-Sebastian Bolz - Co-founder of Aphaia Pharma
30 maart 2026 · 28 min
Welcome to another episode of The BioHub. Lees meer
Today I’m joined by Steffen-Sebastian Bolz — scientist, physician, entrepreneur, and Co-Founder of Aphaia Pharma, a clinical-stage biotech developing precision-targeted drug formulations to treat and prevent metabolic disorders like obesity and prediabetes.
We’ll be talking about the science behind Aphaia, why they’re not building with an exit in mind, and how staying lean and under the radar has helped them advance to Phase 2.
-
Episode 136 - Philippe Chambon - CEO & Co-Founder EG427
25 maart 2026 · 23 min
In this episode of The BioHub Podcast, Max sits down with Dr. Philippe Chambon, CEO and Co-Founder of EG 427. Lees meer
After more than 30 years in pharma and venture capital — raising over $1 billion to back life science companies — Philippe has made the move from investor to operator, now leading EG 427.
The company is pioneering a new approach to neurological disease with pinpoint DNA medicine, designed for precise and durable delivery.
In this conversation, Philippe shares his journey into the CEO seat, the inspiration behind EG 427, and why he believes Europe — and France in particular — are entering a new era for biotech innovation.
-
Episode 135 - Yerem Yeghiazarians - Co-Founder & CEO Soley Therapeutics
25 maart 2026 · 28 min
Today’s guest is Dr. Yerem Yeghiazarians — a leading interventional cardiologist, professor of medicine at the University of California, San Francisco, and a physician-scientist working at the cutting edge of cardiovascular innovation. Lees meer
With medical training from Johns Hopkins and advanced cardiology specialization at Brigham and Women’s Hospital, Dr. Yeghiazarians has spent over two decades at UCSF treating complex heart disease and advancing the field of interventional cardiology.
Dr. Yeghiazarians is the co-founder of Soley Therapeutics, a biotech company focused on using AI to better understand how cells respond to stress, injury, and disease — with the goal of transforming how new drugs are discovered and developed.
Alongside this, he directs translational research exploring how stem cell therapies can repair heart damage after heart attacks, bridging fundamental science with real-world clinical impact.
From the cath lab to the biotech startup world, his career sits at the intersection of medicine, technology, and entrepreneurship — and today, we’ll explore that journey, the future of drug discovery, and what it takes to turn scientific insight into meaningful breakthroughs.
-
Episode 134 - Amit Etkin - Founder & CEO Alto Neuroscience
20 maart 2026 · 35 min
In this episode of The BioHub Podcast, Max sits down with Amit Etkin, Founder and CEO of Alto Neuroscience. Lees meer
Psychiatry is one of the few areas in medicine still dominated by trial and error.
Amit is trying to change that.
A trained psychiatrist and neuroscientist, Amit founded Alto to bring precision medicine into mental health — using biomarkers to better match patients with the treatments that actually work for them.
In this conversation, we get into why CNS drug development has historically struggled, what’s broken in the current system, and how a more data-driven approach could reshape the future of psychiatry.
We also talk about Amit’s journey from academia to founder, the realities of building in a tough market, and why now might finally be the turning point for neuroscience.
A thoughtful, honest conversation tackling one of the hardest problems in medicine. 🧠
-
Episode 133 - Ronald Li & James Kim - CEO and Chief Corporate at Medera respectively ficer at M
19 maart 2026 · 23 min
We were delighted to be joined by James Kim (Chief Corporate Officer) and Ronald Li (Chief Executive Officer), at Medera Biopharmaceuticals. Lees meer
Medera is a company at the forefront of pharmaceutical innovation, focused on advancing next-generation therapies and building a globally competitive platform across research, development, and commercialization. As the industry continues to evolve — driven by scientific breakthroughs, regulatory complexity, and shifting market dynamics — Medera is positioning itself to play a meaningful role in shaping what comes next.
James and Ronald sit right at the center of that journey. Between them, they bring deep experience across strategy, operations, and scaling healthcare businesses, with a strong focus on translating innovation into real-world impact.
-
Episode 132 - Fabian Gerlinghaus - Co-Founder & CEO of Cellares
18 maart 2026 · 24 min
On this episode we welcome Cellares' co-founder, Fabian Gerlinghaus, to discuss their revolutionary, fully automated, cell therapy manufacturing platform. Lees meer
Cell therapies work - the science is proven. Fabian & the team's mission is to deliver these life-changing therapies at scale, to change more patient's lives.
On this episode we talk through Fabian's background in robotics, his move to California and the life sciences, and how he and co-founder Omar Kurdi started the Cellares story.
Looking ahead, we dig into the technology and, latest milestones (including recently starting GMP manufacturing), whilst also talking through plans for international expansion, and the impressive Series D funding that journey.
-
Episode 131 - Dipal Doshi - CEO of Entrada Therapeutics
17 maart 2026 · 53 min
Today, we’re joined by Dipal Doshi, a leader at theforefront of modern biotechnology and rare disease innovation. As CEO of Entrada Therapeutics, Dipal has helped build the company from its earliest days into a clinical-stage pioneer focused on unlocking intracellular therapies. Lees meer
With a career that spans investment banking at MerrillLynch, global pharma at Eli Lilly and Company, and senior leadership roles at Amicus Therapeutics, Dipal brings a unique blend of financial, strategic, and commercial expertise to the biotech world.
Now Dipal's leading Entrada Therapeutics, who are aclinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of genetic medicines that engage intracellular targets that have long been considered inaccessible. Through proprietary, versatile and modular approaches, they are advancing a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases, among others.
-
Episode 130 - Barry Quart - CEO Connect Biopharma
16 maart 2026 · 30 min
In this episode of The BioHub Podcast, Max sits down with Barry Quart, CEO of Connect Biopharma and one of the most experienced biotech leaders in the industry. Lees meer
Barry’s career spans more than three decades across biotech and pharma, including founding Ardea Biosciences (acquired by AstraZeneca) and leading Heron Therapeutics, where he helped bring multiple drugs through development and approval. Across his career he has played a role in nine FDA-approved medicines.
In this conversation, Barry shares the lessons he’s learned building biotech companies, what it really takes to develop successful drugs, and how he thinks about leadership in an industry defined by risk and long timelines.
They also dive into Connect Biopharma, the company’s strategy in inflammatory diseases, and the potential of their lead program targeting the IL-4 pathway in asthma and other respiratory conditions.
It’s a conversation about building companies, developing medicines, and navigating the realities of biotech.
-
Episode 129 - Bob Clarke - CEO & Co-Founder at Kinaset Therapeutics
12 maart 2026 · 27 min
Today’s guest is Robert Clarke, the CEO of Kinaset — acompany at the forefront of next-generation therapeutics and biotechnology innovation. Lees meer
Robert brings a unique blend of scientific curiosity, strategic leadership, and entrepreneurial drive to the biotech world. With a background spanning life sciences, investment, and company building, he has spent much of his career working at the intersection of science and commercialization — helping translate breakthrough research into real-world medical solutions.
At Kinaset, Robert leads the company’s mission to developinnovative therapies aimed at improving outcomes for patients with serious diseases. Under his leadership, the company has been advancing novel approaches in drug discovery and development, building partnerships across the biotech ecosystem, and positioning Kinaset as an emerging player in the global life sciences landscape.
-
Episode 128 - Emily Gransky - VP, Talent @ Formation Bio
11 maart 2026 · 20 min
The biggest bottleneck in drug development is no longer discovery, it's in the clinic. Formation Bio's proprietary AI-native platform is changing drug development to bring new treatments to patients faster and more efficiently. Lees meer
We catch up with Emily Gransky, who is shaping the talent strategy behind one of biotechs most exciting stories.
Emily previously shaped Flagship & RA Ventures TA strategies, and played a key role in scaling Bluebird Bio from 300 to 800 headcount.
During this episode, we discuss how the team are leveraging AI to drive efficiency and quality throughout the recruitment process. We also get Emily's take on the rapid evolution of AI and it's impact on biotech talent.
-
Episode 127 - Ann Belien - Founder and CEO Rejuvenate Biomed
10 maart 2026 · 28 min
Ann is the Founder and CEO of Rejuvenate Biomed, a clinical-stage biotechnology company developing combination therapies aimed at targeting the biological mechanisms behind age-related diseases. With more than two decades of experience in pharmaceutical research and development, she has built a career focused on translating cutting-edge science into therapies that can improve patients’ lives. Lees meer
Before launching Rejuvenate Biomed in 2017, Ann held leadership roles at Janssen Pharmaceuticals, part of Johnson & Johnson, where she worked across drug discovery, development, and innovation strategy. Her work has spanned multiple therapeutic areas including oncology, neurology, immunology, and infectious diseases.
Ann earned her PhD in neuro-oncology from the University of Zurich and conducted postdoctoral research at ETH Zurich, building a strong scientific foundation that she later brought into the biotech industry.
-
Episode 126 - Catherine Isted - CFO of Santhera Pharmaceuticals
9 maart 2026 · 26 min
In this episode of The BioHub, I’m joined by Catherine Isted, Chief Financial Officer of Santhera Pharmaceuticals. Lees meer
Catherine’s career journey is a unique one, from starting as a bench scientist, to nearly two decades in healthcare investment banking, and now leading finance at multiple biotech companies.
In this International Women’s Day special, we talk about her path through the industry, the importance of diversity of thought in biotech, her experiences building a career in leadership, and her advice for young women looking to enter the field.
-
Episode 125 - Rich Daly - CEO of Catalyst Pharma
5 maart 2026 · 24 min
Today I’m joined by Rich Daly, CEO of Catalyst Pharmaceuticals — one of the standout rare-disease success stories in the industry and recently named one of America’s most successful small-cap companies by Forbes. Lees meer
Rich has spent more than 25 years leading organisations across biotech and pharma — including AstraZeneca, BeyondSpring, CARsgen, and others — and now he’s steering Catalyst as they expand their portfolio, grow their footprint, and continue delivering life-changing treatments for patients with rare neuromuscular and neurological diseases.
We talk about what drew him to Catalyst, how the company thinks about growth, patient service, and rare-disease strategy, how they find the right drugs in a competitive market, and how Catalyst continues to outperform despite the volatility across biotech.
Let’s get into it.
-
Episode 124 - Jason Ehrlich - CEO & Co-Founder of Ollin Biosciences
26 februari 2026 · 36 min
We were delighted to welcome Jason Ehrlich, Co-Founder and CEO of Ollin Biosciences onto the BioHub. Ollin are a clinical-stage biotechnology company focused on advancing next-generation therapies form serious eye diseases, including wet age-related macular degeneration anddiabetic macular edema. Lees meer
Before launching Ollin, Jason served as Chief MedicalOfficer and Chief Development Officer at Kodiak Sciences, where he led clinical development in retinal disease. Earlier in his career, he held senior leadership roles at Genentech, one of the pioneers in biologic medicines, helping advance therapies that have transformed care for patients with vision-threatening conditions.
Trained as both a physician and a scientist, Jason brings arare blend of clinical insight, translational research expertise, and strategic leadership. His career sits at the intersection of medicine, innovation, and company building — with a clear focus: delivering meaningful, durable therapies to patients who risk losing their sight.
-
Episode 123 - Adam Mendelsohn - CEO Vivani Medical
25 februari 2026 · 32 min
In this episode of The BioHub, I’m joined by Dr. Adam Mendelsohn, Co-Founder and CEO of Vivani Medical. Lees meer
Adam’s journey spans bioengineering at UCSF and UC Berkeley to founding Nano Precision Medical and now leading Vivani following its 2022 merger. Vivani is developing long-term, sub-dermal drug implants designed to transform treatment for chronic diseases such as obesity and diabetes.
We discuss the science behind the platform, why long-acting implants could shift the treatment paradigm, what’s happening at Vivani right now, and what it takes to build and finance a biotech company in today’s market.
-
Episode 122 - Todd Zavodnick - CEO of Excellergy
24 februari 2026 · 24 min
🎙 New Episode Live – Todd Zavodnick, CEO of Excellergy Lees meer
Todd Zavodnick is the CEO of Excellergy, a clinical-stage biotechnology company redefining allergy treatment. Their mission? To make therapies faster, more effective, and far more convenient for patients — transforming the experience of managing allergies.
Before Excellergy, Todd built a track record of leadership in biotech, bringing together scientific rigor and strategic vision to tackle complex challenges in patient care.
In this episode, we discuss:
Excellergy’s approach to improving existing allergy therapies and what sets them apart in the field.
Clinical milestones, including their Phase 1 launch in Australia and plans for Phase 2 next year.
The patient impact — how Excellergy is aiming to reduce wait times and make treatment truly transformative.
Whether you’re interested in biotech innovation, clinical development, or patient-centric therapies, this conversation is packed with insight.
-
Episode 121 - Terry Rosen: CEO & Co-Founder of Arcus Biosciences
19 februari 2026 · 36 min
Today’s guest is Terry J. Rosen, a scientist-entrepreneur who has helped shape the modern era of cancer immunotherapy. Lees meer
Dr. Rosen is the co-founder and CEO of Arcus Biosciences, a clinical-stage biotechnology company focused on developing innovative immuno-oncology therapies and combination treatments designed to transform outcomes for patients with cancer. Before launching Arcus, he co-founded Flexus Biosciences, which was acquired by Bristol-Myers Squibb in 2015—an early validation of his vision in immune-based therapies.
Across his career, Terry has held senior scientific and leadership roles at major biopharmaceutical organizations including Amgen, Pfizer, and Abbott Laboratories, building a track record that bridges rigorous medicinal chemistry with bold company creation.
In this we discuss:
Arcus' pipeline and what makes them stand out from other companies in the immuno-oncology field
What makes Arcus a compelling investment opportunity today and how they balance the long timelines and risks of drug development with the expectations of public markets and investors?
The key milestones for Arcus in the next year to18 months that the scientific and investment communities should be paying attention to
-
Episode 120 - Thijs Spoor - CEO Perspective Therapeutics
18 februari 2026 · 24 min
In this episode of The BioHub, I’m joined by Thijs Spoor, CEO of Perspective Therapeutics. Lees meer
Thijs has taken an unconventional path to the CEO seat, bringing decades of leadership experience across healthcare and capital markets into one of the most exciting areas of biotech: targeted radiopharmaceuticals.
We talk about his journey into the industry, the science and vision behind Perspective, the company’s recent $175M raise, and the milestones that could define their next phase of growth. A great conversation about bold strategy, differentiated science, and building momentum in today’s market.
-
Episode 119 - Erik van den Berg - CEO of Memo Therapeutics
16 februari 2026 · 24 min
Prior to JPM 2026 and the news of their recent CSL collaboration, I spoke to Memo Therapeutics' CEO, Erik van den Berg for an episode of The BioHub Podcast. Lees meer
Memo are preparing for a global ph3 trial of Potravitug, their antibody against BK polyomavirus infection in kidney transplant recipients. BKPyV infection can lead to nephropathy, loss of kidney function, as well as organ failure, rejection & death, with the virus residing in up to 90% of the total population.
Erik joins us to walk through Memo's late-stage plans, as well as their DROPZYLLA platform, and their early stage oncology programs. He also shares his insight from a varied journey through biotech leadership, including two current Chair roles with former BioHub guests - TargED & Step Pharma.
-
Episode 118 - Declan Doogan - CEO & Executive Chairman of Causeway Therapeutics
12 februari 2026 · 29 min
We were delighted to welcome Declan Doogan, CEO of Causeway Therapeutics, onto The BioHub! Declan is a highly respected leader in the biopharmaceutical industry, with decades of experience spanning drug development, clinical research, and executive leadership at some of the world’s leading pharmaceutical companies. Lees meer
Throughout his career, he has played a pivotal role in advancing innovative therapies from early discovery through to global commercialization. At Causeway Therapeutics, he is leading the charge in developing breakthrough treatments aimed at addressing serious and underserved medical needs.
In this we discuss:
Entrepreneurship and building a biotech having spent decades in Pharma
Causeway's recent encouraging clinic results and what makes there approach different to what's out there already
How Causeway are thinking about the pipeline and upcoming milestones
-
Episode 117 - Raj Devraj - CEO Rectify Pharma
11 februari 2026 · 35 min
In this episode of The BioHub, I’m joined by Raj Devraj, CEO of Rectify Pharma and Venture Partner at Atlas Venture. Lees meer
Raj has spent his career building biotech companies around bold science, including co-founding Disarm Therapeutics, which was acquired by Eli Lilly. Now he’s doing it again with Rectify.
We talk about starting companies from zero, building the right teams early, de-risking new ventures, and the realities of fundraising in today’s biotech market. A practical, honest conversation with a true biotech builder.
-
Episode 116 - Jim Jenson - Morphoceuticals
10 februari 2026 · 24 min
We were delighted to Welcome Jim Jenson, CEO of Morphoecueticals a TechBio company focused on understanding and manipulating the bioelectrome to induce regeneration and treat disease.
-
Episode 115 - Simeon George - CEO & Co-Founder of SR One Capital Management
10 februari 2026 · 24 min
We were delighted to welcome Simeon George, the CEO and Managing Partner of SR One Capital Management, a global biotech venture capital firm he helped spin out of GSK, onto the BioHub! He’s a physician by training, with an MD from the University of Pennsylvania, an MBA from Wharton, and a background that also includes time at Bain & Company and Goldman Sachs. Lees meer
Over the years, Simeon has helped build and back some of the most impactful companies in modern biotech, including CRISPR Therapeutics, Turning Point Therapeutics, and Principia Biopharma, among many others. He’s also a co-founder and board member of multiple biotech companies, working closely with scientists and founders to bring new medicines to patients
-
Episode 114 - Martijn Negen - COO of VarmX
9 februari 2026 · 36 min
We're joined by Martijn for an engaging discussion on VarmX's latest milestones & the wider biotech market. Lees meer
In Q4 2025, VarmX signed a strategic collaboration with CSL to fully fund a global ph3 trial & pre-launch readiness for their lead asset VMX-C001 - a novel treatment to help restore blood coagulation in patients requiring urgent surgery or experiencing severe bleeding while on FXa DOACs.
Martijn shares insight on how the deal came about, what it could mean for patients and VarmX in future, and why CSL are the right partner to develop & deliver VMX-C001 globally.
-
Episode 113 - Kim Hazen- Chief People Officer at Fulcrum Therapeutics
5 februari 2026 · 40 min
Today’s guest is Kim Hazen, a seasoned people and culture leader with more than two decades of experience shaping organizations at the intersection of science, business, and talent. Lees meer
Kim is currently the Chief People Officer at Fulcrum Therapeutics, where she leads human resources and culture for a clinical-stage biotech company focused on developing treatments for rare genetic diseases. Over the course of her career, she’s built and scaled people strategies across both life sciences and financial services, holding senior HR leadership roles at organizations like the Broad Institute of MIT and Harvard, Warp Drive Bio, Aegerion Pharmaceuticals, and several major financial institutions.
In this we discuss:
Kim's 8.5 year journey so far at Fulcrum, from a small, ambitious biotech to the more mature, resilient organization it is today.
Restructuring and the lessons learnt about leadership,communication, and empathy during times of crisis
Kim's new book 'The Culture Shock'
-
Episode 112 - Rodolphe Clerval - CEO of Coave Therapeutics
4 februari 2026 · 29 min
In this episode of The BioHub, I’m joined by Rodolphe Clerval, CEO of Coave Therapeutics. Lees meer
Rodolphe’s journey into the CEO seat wasn’t a traditional one. He moved from science into investment banking, then into major business development roles, before stepping into leadership at multiple biotech companies.
We talk about that unconventional path, the story behind Coave’s evolution and rebrand, and why their precision gene therapy approach is so exciting. It’s a thoughtful conversation about mindset, leadership, and what it really takes to build in small biotech.
-
Episode 111 - Kevin Pojasek - President and CEO of Enara Bio
3 februari 2026 · 34 min
We were delighted to be joined by Kevin Pojasek who's the President and CEO of Enara Bio. Lees meer
Enara Bio is shining a light on Dark Antigen and T-cell biology to develop cancer immunotherapies designed to improve treatment outcomes for broad populations of cancer patients with solid tumors. There pioneering EDAPT® platform enables us to discover cancer-specific antigens from previously uncharted genomic ‘dark matter’. The result is a growing library of Dark Antigens that can address the need for novel, cancer-specific targets in solid tumors.
In this we cover:
The spark that led to the founding of Enara Bio
Enara's platform EDAPT® and how it finds dark antigens in tumors.
Where the field of T-Cell therapy for solid tumors is today.
The importance of culture in early stage biotech, and how the company has been built around putting people first.
The next major milestones for Enara Bio.
-
Episode 110 - JPM Special - Maureen Hillenmeyer - CEO & Founder Hexagon Bio
28 januari 2026 · 7 min
JPM Special — Maureen Hillenmeyer, CEO & Founder of Hexagon Bio Lees meer
In this JPM Special episode of The BioHub, I’m joined by Maureen Hillenmeyer, CEO and Founder of Hexagon Bio.
Maureen has built Hexagon around a bold idea: using genomics, computation, and the biology of natural products to unlock entirely new medicines. At JPM, we sat down to talk about what it really takes to build a platform company in today’s market — from scientific conviction and capital discipline to leadership, culture, and long-term vision.
We also discuss:
What makes Hexagon’s approach fundamentally different
How Maureen thinks about risk, focus, and scale as a founder-CEO
The realities of building biotech through multiple market cycles
A thoughtful, grounded conversation with one of the most impressive founders in the space.
-
Episode 109 - Mike Exton - CEO Lexicon Pharma
26 januari 2026 · 32 min
I’m here with Mike Exton, the CEO of LexiconPharmaceuticals. Lees meer
Mike joined Lexicon in 2024 after two decades of leadershipacross Novartis and Eli Lilly, where he helped launch some of the biggest cardiovascular drugs in the world — including Entresto.
Now he’s leading Lexicon through a bold new chapter, with agenomics-driven pipeline focused on cardiometabolism and neuroscience, and a strategy built around delivering best-in-class or first-in-class medicines in areas of real unmet need.
Mike, great to have you here
-
Episode 108 - JPM Special - Dirk Thye, CEO Quince Therapeutics
26 januari 2026 · 12 min
In our first JPM Special 2026, we’re joined by Dirk Thye, CEO of Quince Therapeutics, as the company approaches a defining Phase 3 readout. A candid conversation about high-stakes data, leadership under pressure, and what a true do-or-die moment looks like in biotech. Lees meer
-
Episode 107- Kevin Marks - CEO Delphia Therapeutics
22 januari 2026 · 30 min
Today’s guest is Kevin Marks, a biotech entrepreneur and the founder and CEO of Delphia Therapeutics. Kevin has spent his career at the forefront of cancer drug discovery, working across research, strategy, and company building with a singular focus on translating breakthrough science into meaningful medicines for patients. Before founding Delphia, he built deep experience in oncology and precision medicine, helping advance novel therapeutic programs and navigating the complex path from early discovery to clinical development. At Delphia Therapeutics, Kevin is leading the development of a new approach to precision oncology known as activation lethality—an emerging strategy designed to uncover previously untapped cancer vulnerabilities and deliver more targeted, effective treatments. Lees meer
With a background that blends rigorous science, entrepreneurial leadership, and a patient-first mindset, Kevin brings a thoughtful perspective on the future of cancer therapy, innovation in biotech, and what it truly takes to build a science-driven company from the ground up. We’re excited to have him with us today.